1. Home
  2. LGN vs INDV Comparison

LGN vs INDV Comparison

Compare LGN & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGN

Legence Corp.

N/A

Current Price

$89.72

Market Cap

3.6B

Sector

N/A

ML Signal

N/A

Logo Indivior PLC

INDV

Indivior PLC

HOLD

Current Price

$37.36

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGN
INDV
Founded
1963
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.7B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
LGN
INDV
Price
$89.72
$37.36
Analyst Decision
Strong Buy
Analyst Count
17
0
Target Price
$59.50
N/A
AVG Volume (30 Days)
2.1M
1.5M
Earning Date
05-15-2026
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
8100.00
EPS
N/A
0.69
Revenue
N/A
$1,239,000,000.00
Revenue This Year
$53.66
N/A
Revenue Next Year
$11.99
N/A
P/E Ratio
N/A
$22.82
Revenue Growth
N/A
4.29
52 Week Low
$28.31
$10.91
52 Week High
$87.30
$39.33

Technical Indicators

Market Signals
Indicator
LGN
INDV
Relative Strength Index (RSI) 82.84 72.47
Support Level $42.97 $32.43
Resistance Level N/A $37.83
Average True Range (ATR) 3.74 1.50
MACD 1.15 0.53
Stochastic Oscillator 99.32 71.67

Price Performance

Historical Comparison
LGN
INDV

About LGN Legence Corp.

Legence Corp is a provider of engineering, installation and maintenance services for mission-critical systems in buildings. It focuses on high-growth sectors that have technically demanding buildings, including technology, life sciences, healthcare and education. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting and building controls in existing facilities to make them more energy efficient and sustainable.

About INDV Indivior PLC

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Share on Social Networks: